Loading
companiesCompany
Wigen Biomedicine Technology (Shanghai)
Wigen Biomedicine Technology (Shanghai) is a China-based biotechnology company running 2 late-stage cancer trials of WJB001.
Also called: Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Overview
Wigen Biomedicine Technology (Shanghai), based in Shanghai, China, is a biotechnology company. Wigen Biomedicine develops innovative anti-tumour drugs using small-molecule covalent/allosteric, PROTAC and drug-conjugate technology platforms. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing WJB001. The largest, NCT05773820 (A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumours), plans to enrol 210 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Shanghai, CN
Scorecard
All companies#472of 1244 companies, score 6
- phase 1/2 +1
- modalities +2
- registry trials +3
0 approved, 0 in phase 3, 1 earlier, 0 targets, 2 registry studies. Formula on the scorecards page.
Type
Stage
Growth stage
Website
Founded
2018
Phase 2Small-molecule inhibitor
WJB001 is a small-molecule inhibitor from Wigen Biomedicine Technology (Shanghai) Co., Ltd., in registered phase 2 trials for metastatic cancer.
Similar pages
- CompanyPregLem
- CompanyAgennix
- CompanyLisata Therapeutics
- CompanyImmunitor
- CompanyEmergent BioSolutions
- CompanyHarbour BioMed
- CompanyVion Pharmaceuticals
- CompanyCyclacel Pharmaceuticals
technologies
drugs
Phase 2Small-molecule inhibitor